Find Industry reports, Company profilesReportLinker ...
Find Industry reports, Company profilesReportLinker an...
Find Industry reports, Company profilesReportLinker and...
Find Industry reports, Company profilesReportLinker and...
Find Industry reports, Company profilesReportLinker ...
Find Industry reports, Company profilesReportLinker ...
of 6

Polycystic Kidney Disease ' Pipeline Review, H2 2012

Polycystic Kidney Disease ' Pipeline Review, H2 2012 Summary Global Markets Direct's, 'Polycystic Kidney Disease - Pipeline Review, H2 2012', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Polycystic Kidney Disease, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Polycystic Kidney Disease. Polycystic Kidney Disease - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - A snapshot of the global therapeutic scenario for Polycystic Kidney Disease.- A review of the Polycystic Kidney Disease products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages.- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.- Coverage of the Polycystic Kidney Disease pipeline on the basis of route of administration and molecule type.- Key discontinued pipeline projects.- Latest news and deals relating to the products. Reasons to buy - Identify and understand important and diverse types of therapeutics under development for Polycystic Kidney Disease.- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.- Devise corrective measures for pipeline projects by understanding Polycystic Kidney Disease pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Published on: Mar 4, 2016
Source: www.slideshare.net


Transcripts - Polycystic Kidney Disease ' Pipeline Review, H2 2012

  • 1. Find Industry reports, Company profilesReportLinker and Market Statistics >> Get this Report Now by email!Polycystic Kidney Disease Pipeline Review, H2 2012Published on September 2012 Report SummaryPolycystic Kidney Disease Pipeline Review, H2 2012SummaryGlobal Markets Directs, Polycystic Kidney Disease - Pipeline Review, H2 2012, provides an overview of the indications therapeuticpipeline. This report provides information on the therapeutic development for Polycystic Kidney Disease, complete with latest updates,and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development forPolycystic Kidney Disease. Polycystic Kidney Disease - Pipeline Review, Half Year is built using data and information sourced fromGlobal Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured pressreleases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicateddisease.Scope- A snapshot of the global therapeutic scenario for Polycystic Kidney Disease.- A review of the Polycystic Kidney Disease products under development by companies and universities/research institutes based oninformation derived from company and industry-specific sources.- Coverage of products based on various stages of development ranging from discovery till registration stages.- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.- Coverage of the Polycystic Kidney Disease pipeline on the basis of route of administration and molecule type.- Key discontinued pipeline projects.- Latest news and deals relating to the products.Reasons to buy- Identify and understand important and diverse types of therapeutics under development for Polycystic Kidney Disease.- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitiveadvantage.- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.- Devise corrective measures for pipeline projects by understanding Polycystic Kidney Disease pipeline depth and focus of Indicationtherapeutics.- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects toenhance and expand business potential and scope.- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.Polycystic Kidney Disease Pipeline Review, H2 2012 (From Slideshare) Page 1/6
  • 2. Find Industry reports, Company profilesReportLinker and Market Statistics >> Get this Report Now by email! Table of ContentTable of ContentsTable of Contents 2List of Tables 4List of Figures 4Introduction 5Global Markets Direct Report Coverage 5Polycystic Kidney Disease Overview 6Therapeutics Development 7An Overview of Pipeline Products for Polycystic Kidney Disease 7Polycystic Kidney Disease Therapeutics under Development by Companies 9Polycystic Kidney Disease Therapeutics under Investigation by Universities/Institutes 10Late Stage Products 11Comparative Analysis 11Mid Clinical Stage Products 12Comparative Analysis 12Early Clinical Stage Products 13Comparative Analysis 13Discovery and Pre-Clinical Stage Products 14Comparative Analysis 14Polycystic Kidney Disease Therapeutics Products under Development by Companies 15Polycystic Kidney Disease Therapeutics Products under Investigation by Universities/Institutes 16Companies Involved in Polycystic Kidney Disease Therapeutics Development 17Pfizer Inc. 17Endocyte, Inc. 18Napo Pharmaceuticals, Inc. 19Pharnext SAS 20Polycystic Kidney Disease Therapeutics Assessment 21Assessment by Monotherapy Products 21Assessment by Combination Products 22Assessment by Route of Administration 23Assessment by Molecule Type 25Drug Profiles 27bosutinib - Drug Profile 27Product Description 27Mechanism of Action 27R&D Progress 27KD-019 - Drug Profile 29Product Description 29Mechanism of Action 29R&D Progress 29tolvaptan - Drug Profile 31Product Description 31Mechanism of Action 31R&D Progress 31Polycystic Kidney Disease Pipeline Review, H2 2012 (From Slideshare) Page 2/6
  • 3. Find Industry reports, Company profilesReportLinker and Market Statistics >> Get this Report Now by email!sirolimus - Drug Profile 33Product Description 33Mechanism of Action 33R&D Progress 33CFTR Inhibitors - Drug Profile 34Product Description 34Mechanism of Action 34R&D Progress 34Lisinopril + Telmisartan - Drug Profile 36Product Description 36Mechanism of Action 36R&D Progress 36sirolimus - Drug Profile 37Product Description 37Mechanism of Action 37R&D Progress 37somatostatin - Drug Profile 38Product Description 38Mechanism of Action 38R&D Progress 38Drug For Polysystic Kidney Disease - Drug Profile 39Product Description 39Mechanism of Action 39R&D Progress 39EC-0371 - Drug Profile 40Product Description 40Mechanism of Action 40R&D Progress 40Polycystic Kidney Disease Therapeutics Drug Profile Updates 41Polycystic Kidney Disease Therapeutics - Dormant Products 44Polycystic Kidney Disease Product Development Milestones 45Featured News & Press Releases 45Oct 26, 2009: Napo Acquires Rights To Additional CFTR Technology 45May 05, 2009: Napo Pharmaceuticals Initiates Preclinical Development Of A Novel CFTR Inhibitor Using Preclinical ResourcesOffered By The National Institute Of Allergy And Infectious Diseases (NIAID) 45Jul 08, 2008: FDA Grants Orphan Drug Designation For Alicaforsen 46Appendix 47Methodology 47Coverage 47Secondary Research 47Primary Research 47Expert Panel Validation 47Contact Us 48Disclaimer 48List of TablesNumber of Products Under Development for Polycystic Kidney Disease, H2 2012 7Polycystic Kidney Disease Pipeline Review, H2 2012 (From Slideshare) Page 3/6
  • 4. Find Industry reports, Company profilesReportLinker and Market Statistics >> Get this Report Now by email!Products under Development for Polycystic Kidney Disease Comparative Analysis, H2 2012 8Number of Products under Development by Companies, H2 2012 9Number of Products under Investigation by Universities/Institutes, H2 2012 10Comparative Analysis by Late Stage Development, H2 2012 11Comparative Analysis by Mid Clinical Stage Development, H2 2012 12Comparative Analysis by Early Clinical Stage Development, H2 2012 13Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2012 14Products under Development by Companies, H2 2012 15Products under Investigation by Universities/Institutes, H2 2012 16Pfizer Inc., H2 2012 17Endocyte, Inc., H2 2012 18Napo Pharmaceuticals, Inc., H2 2012 19Pharnext SAS, H2 2012 20Assessment by Monotherapy Products, H2 2012 21Assessment by Combination Products, H2 2012 22Assessment by Stage and Route of Administration, H2 2012 24Assessment by Stage and Molecule Type, H2 2012 26Polycystic Kidney Disease Therapeutics Drug Profile Updates 41Polycystic Kidney Disease Therapeutics Dormant Products 44List of FiguresNumber of Products under Development for Polycystic Kidney Disease, H2 2012 7Products under Development for Polycystic Kidney Disease Comparative Analysis, H2 2012 8Products under Development by Companies, H2 2012 9Products under Investigation by Universities/Institutes, H2 2012 10Late Stage Products, H2 2012 11Mid Clinical Stage Products, H2 2012 12Early Clinical Stage Products, H2 2012 13Discovery and Pre-Clinical Stage Products, H2 2012 14Assessment by Monotherapy Products, H2 2012 21Assessment by Combination Products, H2 2012 22Assessment by Route of Administration, H2 2012 23Assessment by Stage and Route of Administration, H2 2012 24Assessment by Molecule Type, H2 2012 25Assessment by Stage and Molecule Type, H2 2012 26Polycystic Kidney Disease Pipeline Review, H2 2012 (From Slideshare) Page 4/6
  • 5. Find Industry reports, Company profilesReportLinker and Market Statistics >> Get this Report Now by email! Fax Order Form To place an order via fax simply print this form, fill in the information below and fax the completed form to: Europe, Middle East and Africa : + 33 4 37 37 15 56 Asia, Oceania and America : + 1 (805) 617 17 93 If you have any questions please visit http://www.reportlinker.com/notify/contact Order Information Please verify that the product information is correct and select the format(s) you require. Polycystic Kidney Disease Pipeline Review, H2 2012 Product Formats Please select the product formats and the quantity you require. 1 User License--USD 2 000.00 Quantity: _____ Site License--USD 4 000.00 Quantity: _____ Corporate License--USD 6 000.00 Quantity: _____ Contact Information Please enter all the information below in BLOCK CAPITALS Title: Mr Mrs Dr Miss Ms Prof First Name: _____________________________ Last Name: __________________________________ Email Address: __________________________________________________________________________ Job Title: __________________________________________________________________________ Organization: __________________________________________________________________________ Address: __________________________________________________________________________ City: __________________________________________________________________________ Postal / Zip Code: __________________________________________________________________________ Country: __________________________________________________________________________ Phone Number: __________________________________________________________________________ Fax Number: __________________________________________________________________________Polycystic Kidney Disease Pipeline Review, H2 2012 (From Slideshare) Page 5/6
  • 6. Find Industry reports, Company profilesReportLinker and Market Statistics >> Get this Report Now by email! Payment Information Please indicate the payment method, you would like to use by selecting the appropriate box. Payment by credit card Card Number: ______________________________________________ Expiry Date __________ / _________ CVV Number _____________________ Card Type (ex: Visa, Amex…) _________________________________ Payment by wire transfer Crédit Mutuel RIB : 10278 07314 00020257701 89 BIC : CMCIFR2A IBAN : FR76 1027 8073 1400 0202 5770 189 Payment by check UBIQUICK SAS 16 rue Grenette – 69002 LYON, FRANCE Customer signature:   Please note that by ordering from Reportlinker you are agreeing to our Terms and Conditions at http://www.reportlinker.com/index/terms Please fax this form to: Europe, Middle East and Africa : + 33 4 37 37 15 56 Asia, Oceania and America : + 1 (805) 617 17 93Polycystic Kidney Disease Pipeline Review, H2 2012 (From Slideshare) Page 6/6

Related Documents